Live Breaking News & Updates on டேவிட் கிளேர்|Page 6
Stay updated with breaking news from டேவிட் கிளேர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MINNEAPOLIS, April 8, 2021 /PRNewswire/  Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting. This latest addition to the Simple Western product family offers picogram-level sensitivity through chemiluminescence detection along with the ability to perform sequential immunoassays using RePlexâ¢. Abby is accompanied by the latest version of Compass software for Simple Western that adds to its publication-ready data analysis tools extensive lane view annotation capabilities that save hours typically spent editing in other programs. In addition, ProteinSimple has announced the pending release of Stellar⢠NIR and IR modules for Jess⢠which will set a new industry standard for fluorescence Western blotting sensitivity. ....
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13718437. The replay will be available from 11:00 a.m. CDT on Thursday, May 6, 2021 until 11:00 p.m. CDT on Sunday, June 6, 2021. Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical researc ....
Share this article Share this article MINNEAPOLIS, April 6, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. The Asuragen acquisition adds a leading portfolio of best-in-class molecular diagnostic and research products, including genetic screening and oncology testing kits, molecular controls, a Good Manufacturing Practice (GMP)-compliant 50,000 square foot manufacturing facility and a CLIA-certified laboratory, plus a team with deep expertise navigating products through the global diagnostic regulatory environment. Bio-Techne sees multiple growth synergies as a result of this acquisition, including capabilities in productizing lab-developed tests and commercializing innovative molecular products for broader market adopti ....
Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb grandrapidsmn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from grandrapidsmn.com Daily Mail and Mail on Sunday newspapers.
Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test mesabitribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mesabitribune.com Daily Mail and Mail on Sunday newspapers.